Shares of Biogen jumped more than 11 percent after the company announced the U.S. Food and Drug Administration accepted the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease.
Two years after AbbVie and Voyager Therapeutics first forged a collaboration to develop treatments for Alzheimer’s disease, the partnership came to an end after AbbVie terminated the agreement.
CEPI Backs Novavax’s COVID-19 Vaccine Candidate with $384 Million
Biomedical Advanced Research and Development Authority (BARDA), Business, Coalition for Epidemic Preparedness Innovations (CEPI), Coronavirus Vaccines, Funding, Immune Response, Manufacturing, Nanoparticles, Premarket Trading, Shareholders, StocksMaryland-based Novavax snagged $384 in additional grant funding to advance the company’s vaccine candidate against COVID-19.
Shares of ASLAN Pharmaceuticals rose more than 83 percent after the company announced positive preliminary data in an atopic dermatitis study.